Europe gives green light to AbbVie hepatitis C drugs, others

LONDON (Reuters) – European regulators recommended approval for two drugs made by AbbVie to treat hepatitis C, both of which belong to a new generation of medicines that have proved effective in treating a condition that is the most common cause of liver transplants in Europe. Dasabuvir, known commercially as Exviera, and a combination therapy called Viekirax, gave physicians additional treatment options with high cure rates, the European Medicines Agency said on Friday. …
Go to Source